However, with the advent of novel agents, including brentuximab vedotin (BV) and programmed cell death protein 1 monoclonal antibodies (anti-PD-1, nivolumab and pembrolizumab), the treatment landscape for r/r HL is rapidly changing [5,6]. The gene discussed is PDCD1; the disease is Hodgkins lymphoma.